Nuveen LLC Invests $12.24 Million in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Nuveen LLC acquired a significant 2,229,507 shares of Xeris Biopharma, valued at approximately $12.24 million, making it a key institutional investor with a 1.43% stake in the company.
• Analysts have a favorable outlook, with a new price target of $10.00 from HC Wainwright and an overall average target price of $6.58, indicating a Moderate Buy consensus.
• Xeris Biopharma reported a revenue of $67.71 million for the most recent quarter and outperformed EPS expectations by $0.02, setting a positive tone for future performance.

Nuveen LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,229,507 shares of the company's stock, valued at approximately $12,240,000. Nuveen LLC owned 1.43% of Xeris Biopharma as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of XERS. Wealth Enhancement Advisory Services LLC grew its holdings in Xeris Biopharma by 92.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after purchasing an additional 14,986 shares during the period. Millennium Management LLC lifted its position in shares of Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after acquiring an additional 502,853 shares in the last quarter. Two Sigma Advisers LP purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $47,000. Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $45,000. Finally, CWM LLC lifted its position in shares of Xeris Biopharma by 79.3% in the first quarter. CWM LLC now owns 66,972 shares of the company's stock valued at $368,000 after acquiring an additional 29,614 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on XERS. Leerink Partners lifted their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. Oppenheimer lifted their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. HC Wainwright began coverage on Xeris Biopharma in a report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price objective on the stock. Finally, Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Xeris Biopharma currently has an average rating of "Moderate Buy" and an average price target of $7.08.

Insider Activity

In related news, insider Kevin Mcculloch bought 25,000 shares of the stock in a transaction dated Friday, June 13th. The stock was bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Johnson sold 107,500 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the completion of the transaction, the director directly owned 833,483 shares of the company's stock, valued at $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.47% of the company's stock.

Xeris Biopharma Trading Up 0.3%

Xeris Biopharma stock traded up $0.02 during midday trading on Monday, hitting $7.77. The stock had a trading volume of 1,953,434 shares, compared to its average volume of 2,553,253. The stock has a market cap of $1.25 billion, a P/E ratio of -37.00 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.48 and a 12 month high of $7.96. The business has a fifty day moving average price of $5.53 and a 200 day moving average price of $4.86.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.